- Home
- REFI vs LRMR Comparison
REFI vs LRMR Comparison
Compare REFI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- LRMR
- Stock Information
- Founded
- REFI 2021
- LRMR N/A
- Country
- REFI United States
- LRMR United States
- Employees
- REFI N/A
- LRMR N/A
- Industry
- REFI Real Estate Investment Trusts
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- LRMR Health Care
- Exchange
- REFI Nasdaq
- LRMR Nasdaq
- Market Cap
- REFI 274.3M
- LRMR 309.8M
- IPO Year
- REFI 2021
- LRMR N/A
- Fundamental
- Price
- REFI $13.37
- LRMR $3.96
- Analyst Decision
- REFI Strong Buy
- LRMR Strong Buy
- Analyst Count
- REFI 3
- LRMR 8
- Target Price
- REFI $20.00
- LRMR $17.88
- AVG Volume (30 Days)
- REFI 130.8K
- LRMR 1.3M
- Earning Date
- REFI 11-06-2025
- LRMR 10-29-2025
- Dividend Yield
- REFI 15.44%
- LRMR N/A
- EPS Growth
- REFI N/A
- LRMR N/A
- EPS
- REFI 1.84
- LRMR N/A
- Revenue
- REFI $56,608,781.00
- LRMR N/A
- Revenue This Year
- REFI $9.93
- LRMR N/A
- Revenue Next Year
- REFI $4.99
- LRMR N/A
- P/E Ratio
- REFI $7.26
- LRMR N/A
- Revenue Growth
- REFI 2.58
- LRMR N/A
- 52 Week Low
- REFI $12.76
- LRMR $1.61
- 52 Week High
- REFI $16.29
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- REFI 39.83
- LRMR 54.10
- Support Level
- REFI $13.08
- LRMR $3.78
- Resistance Level
- REFI $14.57
- LRMR $4.26
- Average True Range (ATR)
- REFI 0.32
- LRMR 0.27
- MACD
- REFI -0.12
- LRMR -0.00
- Stochastic Oscillator
- REFI 19.46
- LRMR 55.14
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.